Back

Medicus makes CD228V oncology program its principal strategic priority

Verifying
  • Medicus Pharma made CD228V its principal strategic priority in a precision oncology strategy.
  • CD228V is being evaluated in first-in-human Phase 1 study NCT06799533.
  • FDA authorized SkinJect’s SKNJCT-005 registrational Phase 2b study in Gorlin syndrome patients.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.